Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

By Rosa Furneaux and Laura Margottini

The World Health Organization (WHO) and national drug regulators around the world have come under fire for failing to protect children from dangerous chemotherapy drugs.

The WHO plays a major role in protecting people worldwide from bad medicines.

One of the fastest ways it can warn governments about a dangerous or ineffective drug is by issuing a medical product alert. This prompts governments to take action such as recalling the drugs or investigating the manufacturers.

In January 2023, The Bureau of Investigative Journalism (TBIJ) revealed that at least a dozen brands of asparaginase, a key childhood chemotherapy drug, had failed quality tests.

In some cases, they fell well below the standard needed to treat cancer and many contained contaminants such as bacteria. It put an estimated 70,000 children — mostly in low- and middle-income countries — at risk.

One year on, neither national governments nor the WHO have taken meaningful action, with both sides claiming communication breakdown and a lack of evidence.

No alert has been issued by the WHO. And doctors remain frustrated that these brands are still for sale.

“This issue is something that needs to be addressed urgently,” Dr. Gregory Reaman, a scientific director at the U.S. National Cancer Institute, said. “These are children who are already sick and have the potential for being cured. And yet they are given substandard drugs.”

The WHO said it first received information about potentially substandard asparaginase in February 2022.

That report was made by Ronald Barr, professor emeritus in pediatrics at McMaster University, Canada, and a veteran child cancer specialist. “I told them there was an obvious problem,” Barr said.

Researchers in Brazil and India have published studies that showed several brands of asparaginase to be substandard.

He expected the WHO to investigate immediately and to publish the same kind of alert that warned the world about fatally contaminated cough syrup in 2022 and 2023.

However, after an initial conversation with a WHO official, he saw no obvious progress.

The WHO said it did follow up on Barr’s concerns: it searched a monitoring database for entries about asparaginase, conducted a literature review for relevant studies, contacted other WHO teams and got in touch with officials in the countries Barr had named.

But, a WHO spokesperson said, the officials said there was no cause for concern.

At the same time, TBIJ’s reporting sought government data from around the world on any official warnings or recalls they had issued about asparaginase. We found only one country to have taken action.

As well as finding studies that showed major problems with asparaginase brands, our reporting also turned up evidence — such as an internal hospital memo and testimony from doctors — that the WHO’s inquiry appeared to have missed.

Empty efforts

Almost a year after Barr raised his concerns, TBIJ published its investigation, revealing that substandard brands of asparaginase had been shipped to more than 90 countries around the world.

The WHO said it then reconvened its team to discuss the matter and contacted the countries we named.

Last October, a WHO official was invited to speak at a conference for childhood cancer specialists in a session dedicated to concerns about substandard chemotherapies.

The official said that only one country had confirmed that it had experienced problems with asparaginase.

The others said they had never issued any official warnings about the brands named in our article, or else denied that the drugs had ever been found there.

Some countries did not respond at all. (Online attendees were required to agree not to publish or share information from conference speakers, but TBIJ believes it is in the public interest to do so.)

“All investigations rely on impacted [countries] and other stakeholders sharing information with WHO in a timely manner,” a WHO spokesperson told TBIJ. “We carry out extensive desktop research and reach out to our large group of collaborating organisations […] with whom we work on a regular basis.”

The WHO says its investigation is ongoing. But since its initial inquiries, it appears to have resulted in little meaningful action.

“It was, and remains, difficult to establish whether there are any significant issues of concern,” a WHO spokesperson said.

“It doesn’t seem to matter that there’s published evidence,” said Barr. He gave the WHO the contact details of researchers involved in studies conducted in India, in which multiple brands of asparaginase failed drug strength and purity tests.

It appears the WHO never got in touch with them.

TBIJ recently approached researchers involved in seven studies included in our investigation; none had been contacted by the WHO to discuss their results.

A WHO spokesperson said the organization had reviewed nine published articles related to substandard asparaginase, but found there was “no substantive regulatory-relevant scientific evidence provided to demonstrate the quality issues alleged.”

They said the WHO shared these studies with the relevant countries, which bear “primary responsibility” for investigating the products.

The spokesperson said the organization takes the issue of substandard medicines “very seriously,” but would not make documents relating to its asparaginase investigation available to TBIJ.

“In light of WHO’s ongoing discussions with its member states on this matter, WHO is unfortunately not in a position to provide [further] information,” a spokesperson said.

Asked when the inquiries into substandard asparaginase would be concluded, they replied: “I can’t really say.”

The organization said it handles more than 300 reports of substandard medicines every year. While the WHO says that “all reports are investigated,” it also says it requires detailed information on the drugs from government officials before it can take its investigations further.

“WHO relies on countries to share that information,” a spokesperson said. “The WHO mandate does not go beyond that.”

Government action?

The WHO says it has not received any “actionable information” from the governments of countries that appeared in our reporting. This would include, for example, drug samples, “credible test results,” or “clarity on why such a product is classified as substandard or falsified.”

“This is why a global medical product alert has not been issued,” a spokesperson said.

The regulatory agency for Italy — where further TBIJ reporting revealed at least 16 hospitals to have been using a poor-quality brand of asparaginase not approved for use in the European Union — disputes the WHO’s claim, saying it is “unable to clarify” why the organization believes no useful information has been received.

It said it told the WHO what it knew when requested.

For their part, many national governments seem reluctant to take responsibility for the use of dangerous asparaginase in their countries.

In July 2022, the Indian regulatory agency, Central Drugs Standard Control Organization (CDSCO), sent a letter to its regional drug controllers instructing them to look into the issue of poor-quality asparaginase and take “appropriate action.” But little appears to have been done.

“All the CDSCO does is write letters,” said Dinesh Thakur, a drug safety advocate and former generics industry whistleblower. “Most state drug regulators just ignore [them].”

The CDSCO did not respond to a request for comment.

In Italy, 21 senators raised the issue with the country’s health minister last summer and demanded to know how the government would take action to protect children from bad drugs. But as of last week, there had been no reply, said Sandra Zampa, one of the senators in question.

“The minister, indeed the government, has an obligation to answer,” she said. “This particular case is of great importance because it has a very significant impact on people’s lives. I am particularly sorry and concerned about this lack of transparency.”

And while the country’s regulators said they replied to the WHO’s request for information, they have said they are unable to investigate the issue further.

“The agency has no investigative powers, nor is it vested with regulatory functions that would allow it to conduct a ‘national investigation’ or launch fact-finding initiatives” into Italy’s use of poor-quality asparaginase, a spokesperson said.

Which brands of asparaginase are substandard?

“This is a way to shirk [their responsibilities],” Zampa responded. “They should do what they can in the meantime. If not them, who will?”

While the senators have not received a reply for the past six months, the Italian health ministry responded to TBIJ’s questions last week.

It confirmed it is considering the problem of substandard asparaginase, and will decide whether to change national regulations on the import of unauthorized drugs and evaluate “possible quality and safety aspects” of those medicines.

At the European Commission, too, questions were raised early last year by MEPs about the presence of substandard asparaginase on the European market.

The response from Stella Kyriakides, European commissioner for health and food safety, said that “safety features” in existing European directives “guarantee medicine authenticity” for patients. It did not address the use of substandard asparaginase we found in Italy.

While TBIJ’s investigation has made an impact — researchers in the U.S. and Africa have begun developing cheap, simple tests allowing doctors to check the quality of asparaginase — effective action by national regulators to protect children from these drugs remains elusive.

The WHO insists no proven “significant issues of concern” exist.

“The response from WHO defies belief,” Barr said. “Dismissal of evidence published in highly reputable journals following peer review indicates a combination of incompetence and refuge in bureaucracy which should require investigation of the [WHO substandard medicines] team by higher authority within the organisation.”

“They are not at all transparent about what it is they’re actually doing, or what the timeline is,” said Reaman at the National Cancer Institute. “I think patients and families have the right to know.”

Originally published by The Bureau of Investigative Journalism

Rosa Furneaux is an investigative journalist specializing in global health issues, with a particular focus on access to healthcare.

Laura Margottini is an award-winning investigative journalist exploring health, environment and science policy.